NEW YORK (GenomeWeb News) – German firm Medicyte today said that it has licensed lentiviral vector technology from Life Technologies for use in developing cell-based assays.
Medicyte said that it would incorporate the licensed technology into its Upcyte cell products for the biopharma and academic research markets. Financial and other terms of the alliance were not disclosed.
"With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market," Medicyte CEO Joris Braspenning said in a statement.
Medicyte's Upcyte technology is used to proliferate primary cells, which are used in cell-based assays for research, screening, and drug development.